Since its inception in 2019, Emollivet has held a license for Lipidor’s IP relating to the animal segment and a royalty agreement has regulated
On
The purchase price has been set on market terms and amounts to
© Modular Finance, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.185 SEK | -5.13% | -9.76% | -63.29% |
04-22 | Lipidor AB Postpones the Publication of Annual Report for 2023 | CI |
03-21 | Lipidor AB Announces Approval for Start of Phase III Clinical Trial of Psoriasis Candidate AKP02G2 | CI |
Since its inception in 2019, Emollivet has held a license for Lipidor’s IP relating to the animal segment and a royalty agreement has regulated
On
The purchase price has been set on market terms and amounts to
© Modular Finance, source
1st Jan change | Capi. | |
---|---|---|
-63.29% | 530K | |
+39.83% | 731B | |
+31.34% | 586B | |
-7.41% | 348B | |
+16.59% | 319B | |
+0.40% | 273B | |
+13.47% | 235B | |
-6.63% | 203B | |
+7.49% | 202B | |
+3.76% | 159B |